InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery
company with a focus on groundbreaking technologies for the treatment of
spinal cord injuries (SCI) and neurotrauma conditions, today announced
that Brian Luque, Director of Investor Relations, is scheduled to
present at the 2013 Aegis Healthcare Conference to be held September
25-28, 2013 at The Encore at Wynn Las Vegas. The Company’s presentation
will be on Thursday, September 26th at 2:00 p.m. PDT.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a
platform technology to develop treatments for serious diseases and
conditions, including improving function in individuals paralyzed as a
result of traumatic spinal cord injury. The Company was founded in 2005
on the basis of proprietary technology co-invented by Robert Langer,
ScD., Professor at Massachusetts Institute of Technology, and Joseph P.
Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In
2011, the Company earned the prestigious David S. Apple Award from the
American Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. The publicly traded company is
headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. Any forward-looking statements
contained herein are based on current expectations, but are subject to a
number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include,
but are not limited to, risks and uncertainties relating to the
Institutional Review Board process; the Company’s ability to obtain FDA
approval to commercialize its products; the Company’s ability to
develop, market and sell products based on its technology; the expected
benefits and efficacy of the Company’s products and technology in
connection with spinal cord injuries; the availability of substantial
additional funding for the Company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and other risks associated with the Company’s
business, research, product development, regulatory approval, marketing
and distribution plans and strategies identified and described in more
detail in our filings with the SEC, including our Form 10-K and 10-Q’s
and our current reports on Form 8-K. We do not undertake to update these
forward-looking statements made by us.
Copyright Business Wire 2013